Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting ligands for orphan GPCRs.

Enoch S Huang1

  • 1Pfizer Research Technology Center, 620 Memorial Drive, Cambridge, MA 02139 USA. enoch_huang@cambridge.pfizer.com

Drug Discovery Today
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causal reasoning on biological networks: interpreting transcriptional changes.

Bioinformatics (Oxford, England)·2012
Same author

Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.

Current opinion in chemical biology·2011
Same author

Beyond data integration.

Drug discovery today·2008
Same author

PFAAT version 2.0: a tool for editing, annotating, and analyzing multiple sequence alignments.

BMC bioinformatics·2007
Same author

Structure-based maximal affinity model predicts small-molecule druggability.

Nature biotechnology·2007
Same author

Are protein-protein interfaces more conserved in sequence than the rest of the protein surface?

Protein science : a publication of the Protein Society·2003
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
See all related articles

Researchers developed computational methods to identify ligands for orphan G-protein-coupled receptors (GPCRs). These new approaches improve classification accuracy, even for receptors dissimilar to known ones, aiding drug discovery efforts.

Area of Science:

  • Pharmacology
  • Computational Biology
  • Biochemistry

Background:

  • G-protein-coupled receptors (GPCRs) are a major class of drug targets, known for their structural and functional diversity.
  • A significant number of GPCRs are classified as 'orphans,' meaning their endogenous ligands have not yet been identified.
  • Existing computational methods for GPCR classification struggle with orphan receptors that are structurally distinct from characterized ones.

Purpose of the Study:

  • To develop and validate novel computational approaches for identifying cognate ligands of orphan G-protein-coupled receptors.
  • To enhance the accuracy of GPCR classification, particularly for orphan receptors with limited sequence or structural similarity to known receptors.
  • To facilitate the discovery of new therapeutic targets by elucidating the function of orphan GPCRs.

Related Experiment Videos

Main Methods:

  • Utilized advanced machine learning algorithms for sequence and structure-based analysis of GPCRs.
  • Developed novel feature extraction techniques to capture subtle structural and functional similarities.
  • Employed comparative analysis and predictive modeling to identify potential ligand-receptor pairings for orphan GPCRs.

Main Results:

  • The proposed computational methods demonstrated superior performance in classifying orphan GPCRs compared to existing techniques.
  • Successfully identified potential ligands for several previously uncharacterized orphan GPCRs.
  • The models showed robustness even when dealing with orphan receptors exhibiting significant divergence from characterized GPCR families.

Conclusions:

  • The developed computational strategies offer a promising solution for the challenge of orphan GPCR ligand identification.
  • These advancements can accelerate the drug discovery pipeline by providing new avenues for targeting previously intractable receptors.
  • This work contributes to a deeper understanding of GPCRs and their roles in physiological and pathological processes.